{"database": "openregs", "table": "documents", "rows": [["FDA-2006-P-0025-0018", "FDA", "FDA-2006-P-0025", "ICH Harmonised Tripartite Guidelines \"Impurities in New Drug Products Q3B(R2)\" - [Sanofi-aventis U.S., LLC (sanofi-aventis) - Petition Supplement(2)]", "Supporting & Related Material", "SUP-Supplement (Supporting and Related Material)", "2009-07-11T04:00:00Z", 2009, 7, null, null, "2009-07-11T09:15:59Z", null, 0, 0, "0900006480971bb1"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "primary_key_values": ["FDA-2006-P-0025-0018"], "units": {}, "query_ms": 28.76077708788216, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}